Spencer R. Berthelsen, serving as a director at Ionis Pharmaceuticals Inc. (NASDAQ:IONS), completed the sale of 8,000 shares of the company's common stock on June 15, 2026. The total value of the transaction reached $587,920, with the shares sold at a price of $73.49 each. This sale price was closely aligned with the stock's prevailing market price of $73.09 at the time. The transaction was executed under a Rule 10b5-1 trading plan, which Berthelsen established on September 12, 2025, ensuring the sale followed a predetermined schedule rather than being driven by immediate market conditions.
Concurrent with the sale, Berthelsen exercised non-qualified stock options to acquire 8,000 additional shares of common stock. The exercise price for these options was set at $24.42 per share, resulting in a total acquisition cost of $195,360. These options were originally granted on July 1, 2018, and were scheduled to expire on June 30, 2026. Following these transactions, Berthelsen's direct holdings in Ionis Pharmaceuticals common stock stood at 156,013 shares. Additionally, his daughter holds 70 shares indirectly, though Berthelsen has disclaimed beneficial ownership of these securities.
The insider activity comes amid significant developments for Ionis Pharmaceuticals. The company reported that its partner, Biogen, will advance the Alzheimer's drug diranersen to registrational development following promising results from the Phase 2 CELIA study. Ionis has also raised its full-year 2026 total revenue guidance to a range of $875 million to $900 million, an increase from the previous estimate of $800 million to $825 million. In response to this guidance, Oppenheimer raised its price target for Ionis Pharmaceuticals to $110 while maintaining an Outperform rating.
Further positive developments include favorable Phase 3 data from partner GlaxoSmithKline for a hepatitis B treatment, prompting H.C. Wainwright to reiterate a Buy rating with a $125 price target. Wolfe Research also maintained an Outperform rating, setting a $98 price target and noting Ionis's significant 85% reduction in acute pancreatitis. Additionally, Ionis Pharmaceuticals has appointed Ludwig Hantson to its board of directors, bringing over 30 years of experience in the biopharmaceutical and medical device sectors. These developments highlight the company's ongoing progress and strategic moves in the pharmaceutical industry.
Investors analyzing Ionis Pharmaceuticals may consider the stock's remarkable 102% return over the past year. However, data suggests the shares are currently overvalued relative to its Fair Value estimate. This valuation discrepancy presents a key consideration for market participants evaluating the stock's current position.